The performances of the Etest and the disk diffusion methods for testing of the susceptibilities of 235 Candida glabrata isolates to fluconazole and voriconazole were compared with that of the National Committee for Clinical Laboratory Standards (NCCLS) approved standard broth microdilution (BMD) method. The NCCLS method used RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35°C. Etest MICs were determined with RPMI 1640 agar containing 2% glucose (RPG agar) and with Mueller-Hinton agar containing 2% glucose and 0.5 g of methylene blue per ml (MBE agar) and were read after incubation for 48 h at 35°C. Disk diffusion testing was performed with MBE agar, 25-g fluconazole disks, and 1-g voriconazole disks and by incubation at 35°C for 24 h. Overall agreements between the Etest and the BMD MICs obtained with RPG and MBE agars were 91 and 96%, respectively, for fluconazole and 93 and 95%, respectively, for voriconazole. Categorical agreements between the agar-based methods and BMD were 52.3 to 64.7% with fluconazole and 94.8 to 97.4% with voriconazole. The vast majority of the discrepancies by the disk diffusion and Etest methods with fluconazole were minor errors. The agar-based methods performed well in identifying isolates with resistance to fluconazole and decreased susceptibility to voriconazole.The agar-based methods for performing fluconazole and voriconazole susceptibility testing with Candida spp. include both the disk diffusion and the Etest stable-agar-gradient MIC methods (1,3,4,6,8,9,12,16,17). Barry et al. (3) demonstrated that both the disk diffusion and the Etest methods were accurate and precise when they were used to determine the fluconazole susceptibilities of 495 isolates of Candida spp. Although published data for the disk diffusion and Etest methods with voriconazole are limited (4, 9, 12), the results of both methods show good agreement with those of the reference broth microdilution (BMD) method.The studies to date that have documented the efficacies of agar-based methods for the testing of susceptibilities to fluconazole and voriconazole have generally included adequate numbers of Candida albicans isolates but relatively few C. glabrata isolates (1,3,8,17). Among the four most common species of Candida causing bloodstream infections (BSIs; C. albicans, C. glabrata, C. parapsilosis, and C. tropicalis) (10), C. glabrata alone tends to be less susceptible to fluconazole, with a significant percentage of isolates classified as susceptible-dose dependent (S-DD; MIC, 16 to 32 g/ml) or resistant (R; MIC, Ն64 g/ml) (11). This relative lack of susceptibility to fluconazole means that BSIs due to C. glabrata must be treated with high doses of fluconazole (800 mg/day) or an alternative agent pending the results of antifungal susceptibility testing (14). Voriconazole may be useful as an alternative agent, given its excellent activity against C. glabrata isolates that are susceptible (S) or S-DD to fluconazole, but it is not reliably active in vitro against fluconazole-R strains (1...